nanotech investing Group Financial Results as of March 31st 2024 Approved, Continued Growth and EBITDA Margin Expansion, Euro 500 Million Share Buy-Back Program Launched
Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
